# OnCo record paper-isg-sts-1001-gronchi-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-isg-sts-1001-gronchi-lancet-oncol-2017" ;
  schema:name "ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma"@en ;
  schema:description "Trying to match neoadjuvant chemotherapy to sarcoma subtype backfired: standard epirubicin-ifosfamide gave better disease-free and overall survival than the tailored regimens, and in doing so provided evidence that neoadjuvant anthracycline-ifosfamide itself helps high-risk patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30334-0>, <https://pubmed.ncbi.nlm.nih.gov/28499583/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30334-0> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Gronchi A, Ferrari S, Quagliuolo V, et al." ;
  onco:cancers <https://onco.cc/cancers/extremity-soft-tissue-sarcoma/>, <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:trials <https://onco.cc/trials/isg-sts-1001/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .